- Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis.
- The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial.
- IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging.
- A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones.
- Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility.
Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.
Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global market. Its vision centers on redefining how breast imaging is performed—shifting away from adaptations of whole-body scanners or 2D mammography toward a fully dedicated approach optimized for breast anatomy.
The company’s strategy is built around a singular platform with expansion potential. Izotropic is focused on commercializing its lead product through a staged pathway that includes regulatory authorization, clinical validation, and strategic investor engagement. In parallel, the company is developing educational tools and communications platforms to raise awareness among patients, clinicians, and stakeholders about the evolving role of dedicated breast imaging technologies in cancer care.
The company is headquartered in Vancouver, British Columbia, with operations in Sacramento, California.
Technology Portfolio
Izotropic’s flagship product is the IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without compression. The IzoView system was advanced from academic innovation to commercial readiness by Izotropic’s in-house team, building on exclusively licensed technology developed at the University of California, Davis to optimize diagnostic accuracy, patient comfort, and clinical workflow. IzoView integrates proprietary mechanical design, patented hardware innovations, and trade-secret software algorithms, along with AI-driven enhancements designed to improve radiologist performance.
Now in clinical-ready form and housed at Izotropic’s engineering facility in Sacramento, California, IzoView was built under an ISO 13485-compliant quality management system. It is scheduled for use in the company’s planned U.S. clinical trial for FDA market authorization. The device is also central to the company’s broader commercialization strategy, which includes platform extensions and future imaging-based product lines outlined in its recently completed 150-page business plan and financial model.
In preparation for launch, Izotropic is also rolling out strategic awareness platforms. These include a company-hosted podcast and the development of breastct.com, a new educational resource to support patients, clinicians, and stakeholders. These initiatives are designed to enhance engagement, reinforce brand positioning, and build early market traction for IzoView.
Market Opportunity
Izotropic is targeting the global breast imaging market, which is undergoing rapid innovation as healthcare providers seek more accurate, patient-friendly alternatives to traditional mammography. Current screening technologies have well-documented limitations in detecting tumors in women with dense breast tissue, a challenge IzoView directly addresses.
According to a report by MarketsandMarkets, the breast imaging market is projected to grow from $4.3 billion in 2023 to $6.6 billion by 2028, at a compound annual growth rate (CAGR) of 8.9%. Key drivers include the increasing prevalence of breast cancer, the shift toward early detection, and advances in imaging technology such as AI integration and contrast-enhanced diagnostics.
Izotropic’s licensing structure with UC Davis allows the company to pursue either FDA or CE Mark approval, offering flexibility for U.S. and international market entry. Izotropic’s go-to-market plan is supported by ongoing education efforts and a structured clinical strategy, both aligned to accelerate adoption and unlock value in a growing global market.
Leadership Team
Robert Thast, Interim CEO, is the founding executive of Izotropic and has over 30 years of experience leading public companies. He has raised over $100 million in capital, built cross-functional leadership teams, and guided early-stage ventures through public listings and strategic transitions. At Izotropic, he oversees corporate development, financing, and market strategy.
Dr. John Boone, Ph.D., Principal Founder and Director, is a Distinguished Professor of Radiology and Biomedical Engineering at UC Davis. He is a pioneer in breast CT development, having built and tested four dedicated scanners and led trials with nearly 500 women. He has held top roles in AAPM and RSNA and currently serves as Editor-in-Chief of Medical Physics.
Ralph Proceviat, CPA, CFO and Director, brings more than four decades of experience in finance, restructuring, and cross-border operations. He has served as CEO, President, and CFO across multiple sectors and has raised significant capital for both public and private ventures. He is also the founder of C-Suite-Consulting.
Dr. Younes Achkire, Ph.D., Chief Operating Officer and Lead Engineer, is the technical lead behind IzoView. He previously co-founded Zap Surgical Systems and has commercialized FDA-cleared technologies in medtech and clean energy. At Izotropic, he manages engineering, manufacturing, clinical deployment, and operational scale-up.
For more information, visit the company’s website at https://izocorp.com.
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
